Avaliação econômica do tratamento  da degeneração macular relacionada à  idade tipo úmida com as terapias anti-VEGF, aflibercepte ou ranibizumabe, sob  a perspectiva do sistema privado

Nilceia Silva; Cibele Suzuki; Evelyn Christina Volsi

Economic evaluation of the treatment of wet age-related macular degeneration with anti-VEGF therapies, aflibercept or ranibizumab, from the private payer perspective

Authors

Nilceia Silva Novartis Biociências SA. São Paulo, Brasil.
Cibele Suzuki Novartis Biociências SA. São Paulo, Brasil.
Evelyn Christina Volsi Novartis Biociências SA. São Paulo, Brasil.

Abstract

Check out the full article via PDF.

Downloads

Download data is not yet available.

Downloads

PDF (Português (Brasil))

Published

2014-04-20

How to Cite

Silva, N., Suzuki, C., & Volsi, E. C. (2014). Economic evaluation of the treatment of wet age-related macular degeneration with anti-VEGF therapies, aflibercept or ranibizumab, from the private payer perspective. Jornal Brasileiro De Economia Da Saúde, 6(1), 39–40. Retrieved from https://www.jbes.com.br/index.php/jbes/article/view/380